# ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

> **NCT07538401** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 45 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia (CML) in

## Interventions

- **DRUG:** No high risk mutation
- **DRUG:** High Risk Mutation

## Key facts

- **NCT ID:** NCT07538401
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-25
- **Primary completion:** 2028-04-25
- **Final completion:** 2029-04-25
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07538401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07538401, "ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07538401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*